Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia.
Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, Auburn, AL.
J Manag Care Spec Pharm. 2021 Jun;27(6):772-778. doi: 10.18553/jmcp.2021.27.6.772.
50% of prescriptions dispensed in the United States are not taken as prescribed, leading to approximately 125,000 deaths and 10% of hospitalizations per year. Incentives are effective in improving medication adherence; however, information about patient perceptions regarding incentives is lacking. To (1) explore perceived appropriateness of incentives among patients prescribed at least 1 medication for chronic hypertension, hyperlipidemia, heart disease, diabetes, and/or asthma/chronic obstructive pulmonary disease and (2) examine associations between perceived appropriateness and patient characteristics. A cross-sectional online survey was administered via Qualtrics Panels to US adults taking at least 1 prescription medication for a chronic condition. The results describe patient preference for financial or social recognition-based incentive, perceived appropriateness of adherence incentives (5-point Likert scale), self-reported adherence (Medometer), and demographics. Analyses included descriptive statistics with chi-square and independent t-tests comparing characteristics between participants who perceived incentives as being appropriate or inappropriate and logistic regression to determine predictors of perceived appropriateness. 1,009 individuals completed the survey. Of the 1,009 total survey participants, 933 (92.5%) preferred to receive a financial (eg, cash, gift card, or voucher) rather than a social recognition-based incentive (eg, encouraging messages, feedback, individual recognition, or team competition) for medication adherence. 740 participants (73%) perceived medication adherence incentives as being appropriate or acceptable as a reward given for taking medications at the right time each day, whereas 95 (9%) perceived incentives as being inappropriate. Remaining participants were neutral. Hispanic ethnicity (OR = 0.57; 95% CI = 0.37-0.89); income under $75,000 (OR = 0.48; 95% CI = 0.28-0.84); no college degree (OR = 0.60; 95% CI = 0.37-0.96); and adherence (OR = 0.99; 95% CI = 0.98-0.99) were significant predictors. The majority of patients perceived incentives as appropriate and preferred financial incentives over social recognition-based incentives. Perceived appropriateness for medication adherence incentives was less likely among certain groups of patients, such as those with Hispanic ethnicity, lower annual income, no college degree, and higher levels of adherence. These characteristics should be taken into account when structuring incentives. : This study was funded by the Auburn University's Intramural Grants Program. Hansen, Qian, and Garza are affiliated with Auburn University. Hansen has provided expert testimony for Daiichi Sankyo and Takeda on unrelated matters. The other authors have no potential conflicts of interest to declare. This study was presented as a poster presentation at the American Association of Colleges of Pharmacy Annual Meeting held July 2018 in Boston, MA.
50%的处方在美国没有按照规定服用,导致每年约有 12.5 万人死亡和 10%的住院治疗。激励措施在提高药物依从性方面是有效的;然而,关于患者对激励措施的看法的信息是缺乏的。(1)探讨至少有 1 种药物治疗慢性高血压、高血脂、心脏病、糖尿病和/或哮喘/慢性阻塞性肺疾病的患者对激励措施的感知适宜性;(2)检查感知适宜性与患者特征之间的关系。通过 Qualtrics Panels 对美国服用至少 1 种处方药治疗慢性疾病的成年人进行了横断面在线调查。结果描述了患者对基于财务或社会认可的激励措施的偏好、对药物依从性激励措施的感知适宜性(5 分李克特量表)、自我报告的依从性(Medometer)和人口统计学特征。分析包括描述性统计,采用卡方检验和独立 t 检验比较参与者中认为激励措施合适或不合适的特征,并进行逻辑回归以确定感知适宜性的预测因素。共有 1009 人完成了调查。在 1009 名总调查参与者中,933 名(92.5%)更愿意接受基于财务的激励措施(例如现金、礼品卡或代金券),而不是基于社会认可的激励措施(例如鼓励信息、反馈、个人认可或团队竞争),以提高药物依从性。740 名参与者(73%)认为药物依从性激励措施作为每天按时服药的奖励是合适或可以接受的,而 95 名参与者(9%)认为激励措施不合适。其余参与者持中立态度。西班牙裔(OR = 0.57;95% CI = 0.37-0.89);收入低于 75,000 美元(OR = 0.48;95% CI = 0.28-0.84);没有大学学位(OR = 0.60;95% CI = 0.37-0.96);和依从性(OR = 0.99;95% CI = 0.98-0.99)是显著的预测因素。大多数患者认为激励措施是合适的,并且更喜欢基于财务的激励措施而不是基于社会认可的激励措施。在某些患者群体中,如西班牙裔、年收入较低、没有大学学位和较高的依从性,药物依从性激励措施的感知适宜性较低。在制定激励措施时,应考虑到这些特征。本研究由奥本大学内部拨款计划资助。Hansen、Qian 和 Garza 隶属于奥本大学。Hansen 曾就与 Daiichi Sankyo 和 Takeda 无关的事项为其提供专家证言。其他作者没有潜在的利益冲突需要声明。本研究在美国药学院协会年度会议上以海报形式展示,该会议于 2018 年 7 月在马萨诸塞州波士顿举行。